Getein Biotech, Inc (603387.SS)
- Previous Close
8.74 - Open
8.73 - Bid 9.04 x --
- Ask 9.05 x --
- Day's Range
8.70 - 9.08 - 52 Week Range
7.44 - 14.66 - Volume
3,646,664 - Avg. Volume
5,020,230 - Market Cap (intraday)
4.59B - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
18.10 - EPS (TTM)
0.50 - Earnings Date --
- Forward Dividend & Yield 0.40 (4.58%)
- Ex-Dividend Date Sep 27, 2023
- 1y Target Est
--
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection of cardiac troponin I, chemiluminescence, biochemical detection, molecular detection, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, thrombosis and hemostasis, and other technical fields, covering cardiovascular, inflammation, kidney, thyroid function, hormone, glucose metabolism, tumor, blood cells, blood coagulation, and other detection fields. Its product applications include laboratory departments of medical institutions, emergency rooms, health examination center, community clinic, family personal health management, etc. The company was founded in 2002 and is headquartered in Nanjing, China.
www.getein.com.cnRelated News
Performance Overview: 603387.SS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603387.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603387.SS
Valuation Measures
Market Cap
4.43B
Enterprise Value
4.26B
Trailing P/E
17.48
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.07
Price/Book (mrq)
1.77
Enterprise Value/Revenue
2.94
Enterprise Value/EBITDA
14.83
Financial Highlights
Profitability and Income Statement
Profit Margin
17.49%
Return on Assets (ttm)
2.91%
Return on Equity (ttm)
9.64%
Revenue (ttm)
1.45B
Net Income Avi to Common (ttm)
252.78M
Diluted EPS (ttm)
0.50
Balance Sheet and Cash Flow
Total Cash (mrq)
944.73M
Total Debt/Equity (mrq)
28.71%
Levered Free Cash Flow (ttm)
-525.75M
Company Insights: 603387.SS
603387.SS does not have Company Insights